Media coverage about Spring Bank Pharmaceuticals (NASDAQ:SBPH) has trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm scores the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Spring Bank Pharmaceuticals earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 47.1619795255232 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

A number of research firms have recently commented on SBPH. ValuEngine cut Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Dawson James reissued a “buy” rating on shares of Spring Bank Pharmaceuticals in a research note on Monday, August 7th. Cantor Fitzgerald started coverage on Spring Bank Pharmaceuticals in a research report on Wednesday, July 19th. They set an “overweight” rating and a $29.00 price objective on the stock. Finally, Chardan Capital increased their price objective on Spring Bank Pharmaceuticals from $16.50 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, May 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $26.33.

Shares of Spring Bank Pharmaceuticals (SBPH) opened at 15.44 on Tuesday. The company’s 50 day moving average price is $14.69 and its 200 day moving average price is $14.18. Spring Bank Pharmaceuticals has a 52-week low of $6.31 and a 52-week high of $15.73. The stock’s market capitalization is $196.04 million.

In other Spring Bank Pharmaceuticals news, Director David Arkowitz bought 2,500 shares of the company’s stock in a transaction that occurred on Friday, August 4th. The shares were purchased at an average cost of $12.24 per share, for a total transaction of $30,600.00. Following the purchase, the director now directly owns 17,086 shares in the company, valued at $209,132.64. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kurt M. Eichler bought 76,923 shares of the company’s stock in a transaction that occurred on Tuesday, June 27th. The shares were acquired at an average price of $13.00 per share, for a total transaction of $999,999.00. Following the completion of the purchase, the director now owns 582,533 shares in the company, valued at $7,572,929. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 82,423 shares of company stock worth $1,070,159. 17.60% of the stock is owned by company insiders.

TRADEMARK VIOLATION NOTICE: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/09/19/spring-bank-pharmaceuticals-sbph-earning-somewhat-positive-press-coverage-analysis-shows.html.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.

Insider Buying and Selling by Quarter for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Stock Ratings for Spring Bank Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.